Peripheral artery disease market seen reaching $10.8 billion by 2035

Allied Market Research says the global peripheral artery disease market was worth $4.5 billion in 2023 and is projected to reach $10.8 billion by 2035, driven by rising disease prevalence, an aging population and broader use of minimally invasive procedures. The report also points to drugs, hospitals and North America as the leading segment, end-user and region, respectively. Why it matters: - Peripheral artery disease is expected to remain a growing treatment market as more patients need ongoing drug therapy, diagnostic care and interventions. - The forecast points to a larger opportunity for device makers, drugmakers, hospitals and specialty clinics as demand rises through 2035. - The report highlights where investors and market participants may find the strongest growth pockets across products, end users and regions. What happened: - Allied Market Research published a report on the global peripheral artery disease market covering product type and end users from 2024 to 2035. - The market was valued at $4.5 billion in 2023 and is projected to reach $10.8 billion by 2035. - The report estimates the market will grow at a 7.7% CAGR from 2024 to 2035. - The report says demand is being lifted by higher peripheral artery disease prevalence, a larger geriatric population and wider adoption of minimally invasive procedures. - Technological advances in peripheral artery disease treatment devices are expected to create additional growth opportunities. The details: - The drug segment held the largest share in 2023 and is expected to account for three-fifths of market revenue during the forecast period. - Drugs remain central because patients often need them to control blood cholesterol and slow disease progression. - Hospitals accounted for more than half of market revenue in 2023. - Hospitals continue to lead because peripheral artery disease often requires complex diagnostic work, medical management and procedures such as angioplasty, stenting or bypass surgery. - Specialty clinics are expected to post the fastest CAGR over the forecast period. - Specialty clinics can offer lower overhead costs and streamlined care for certain peripheral artery disease services. - North America held more than one-third of market revenue in 2023. - Asia-Pacific is expected to post a notable CAGR over the forecast period. - The report lists Philips N.V., B. Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, Cardinal Health and Abbott among key companies. - The companies have used strategies including product approvals to grow share and defend regional positions. - The report says it examines business performance, operating segments, product portfolios and strategic moves across the competitive landscape. - The report covers North America, Europe, Asia-Pacific and LAMEA. - Allied Market Research also offers a sample PDF report with graphs and figures . - Allied Market Research also offers a purchase inquiry page . Between the lines: - Drug therapy remains the biggest revenue pool, which suggests PAD care still depends heavily on long-term medical management rather than only procedures. - Hospitals dominate because the condition often needs higher-acuity infrastructure, but specialty clinics may gain share by competing on cost and efficiency. - North America leads now, while Asia-Pacific looks positioned for faster expansion as aging and cardiovascular disease burdens rise. What’s next: - The market is likely to keep expanding as diagnosis rates, treatment adoption and device innovation advance through 2035. - Competitive pressure among major manufacturers may intensify as companies pursue approvals and regional share gains. - Specialty clinics and Asia-Pacific could become more important growth channels over the forecast period. The bottom line: - The peripheral artery disease market is on track to more than double by 2035, with drugs, hospitals and North America still anchoring demand while Asia-Pacific and specialty clinics show the fastest momentum.